Jyong Biotech Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Jyong Biotech Ltd. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds10 adding, 12 cuttingOf 2 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow grew 16.1% while net income fell 54.7%: a 71pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Jyong Biotech Ltd.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 2.0% in a year.
Price chart
- 1 day-0.5%
- 1 week+5.6%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-0.06
Growth
- Share count change
- +2.0%
Cash
- Free cash flow (TTM)
- -$3.1M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for MENS from the sources we follow. See filings →
Valuation models
We value Jyong Biotech Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: book value or earnings not available |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Jyong Biotech Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, after the close.
Analysts' consensus
No analyst estimates are published for Jyong Biotech Ltd.: too few analysts cover it.
Positioning
- Short interest
- 0.5% of tradable shares
- Days to cover
- 4.46 at average volume
- Short interest, 1 month
- −13% to October 15, 2026
- Held by institutions
- 1% of shares
- Held by insiders
- 62.2% of shares
- Employees
- 27 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities $16m of assets due within a year against $35m of liabilities due within a year.
- Short-term assets cover long-term liabilities $16m short-term assets against $11m of longer-dated liabilities.
- More cash than debt $1m of cash against $17m of debt.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$3m of operating cash flow against $17m of debt.
- Operating profit covers interest at least five times over Operating income of −$3m against $3m of interest.
Dividends, buybacks and capital spending
- Diluted share count
- +2.0%
- year over year
Who owns it
Funds buying and selling- Reported value
- $1M
- Institutions reporting
- 19
- Shares held vs prior quarter
- ▲ 7.6%
- Positions opened / closed
- 5 / 3
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $538,856 | 260K | 53.3% | ▲ 0.6% |
| Geode Capital Management, LLC | $142,585 | 69K | 14.1% | ▲ 7.2% |
| HRT Financial LP | $104,000 | 50K | 10.3% | ▲ 328.5% |
| Xtx Topco Ltd | $60,167 | 29K | 6.0% | New |
| Renaissance Technologies LLC | $47,403 | 23K | 4.7% | New |
| China Universal Asset Management Co., Ltd. | $25,047 | 12K | 2.5% | ▼ 8.1% |
| State Of Wyoming | $23,201 | 11K | 2.3% | New |
| Morgan Stanley | $12,652 | 6K | 1.3% | ▼ 3.0% |
| Barclays PLC | $12,277 | 6K | 1.2% | ▲ 14.3% |
| Jpmorgan Chase & Co | $11,834 | 5K | 1.2% | ▼ 5.3% |
| UBS Group AG | $8,376 | 4K | 0.8% | ▼ 89.2% |
| Mirae Asset Global Investments Co., Ltd. | $7,038 | 3K | 0.7% | ▼ 12.2% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Jyong Biotech Ltd.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Jyong Biotech Ltd. in brief
- What does Jyong Biotech Ltd. do?
- Jyong Biotech Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Jyong Biotech Ltd.'s stock ticker?
- Jyong Biotech Ltd. trades under the ticker MENS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Jyong Biotech Ltd.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Geode Capital Management, LLC and HRT Financial LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- When is Jyong Biotech Ltd.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Jyong Biotech Ltd. announces its own schedule.
Follow research on Jyong Biotech Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.